DF289
Phase 3Small molecule
DF289 is one of 9 small molecule programs targeting Otitis Externa. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Otitis Externa
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Levaquin
WWim Janssens
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cipro
BayerPhase 3
Voltaren
CCerimon Pharmaceuticals
Phase 2
Ciprodex
PPar Pharmaceutical, Inc.
Phase 3
DF289
SSalvat
Phase 3
DF277
SSalvat
Phase 3
OTO-201
OOtonomy, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DF289. EMBL-EBI & Wellcome Sanger Institute.
- [4]